布洛芬(Ibuprofen) - 药物靶点：COX_在研适应症：动脉导管未闭，慢性疼痛，幼年特发性关节炎_专利_临床

概要

基本信息

简介布洛芬是一种小分子药物，具有 COX 抑制剂的作用。强生公司于 1978 年 8 月批准了该药，主要用于治疗类风湿性关节炎、关节炎、发烧和疼痛等疾病。布洛芬会阻碍产生前列腺素的 COX 酶的活性。这些激素参与炎症和疼痛信号传导。通过减少前列腺素的产生，布洛芬可以减轻炎症并减轻疼痛。多种形式的布洛芬可在柜台购买，包括片剂、胶囊和外用乳膏。虽然布洛芬通常是安全的，但长期使用或高剂量使用会增加胃肠道出血、肾脏损伤和心脏问题等副作用的风险。患者应遵守推荐剂量，如果症状持续或恶化，应寻求医疗建议。

药物类型

小分子化药

别名

(4-isobutylphenyl)-α-methylacetic acid、(RS)-ibuprofen、(±)-2-(p-isobutylphenyl)propionic acid

+ [94]

靶点

COX

作用机制

COX抑制剂(环氧化酶抑制剂)

治疗领域

免疫系统疾病神经系统疾病心血管疾病+ [6]

在研适应症

动脉导管未闭慢性疼痛幼年特发性关节炎+ [27]

非在研适应症

急性疼痛急性呼吸道感染镇痛+ [15]

原研机构

Johnson & Johnson

在研机构

Kaken Pharmaceutical Co., Ltd.

中山万汉制药有限公司

越洋医药开发（广州）有限公司

+ [19]

非在研机构

Oxford Pharmascience Ltd.

Apsen Farmaceutica S/A北京爱力佳医药科技有限公司

+ [14]

最高研发阶段批准上市

首次获批日期

中国 (1966-01-01),

关节炎发热疼痛

最高研发阶段(中国)批准上市

特殊审评孤儿药 (美国)、优先审评 (中国)

登录后查看时间轴

结构

分子式C13H18O2

InChIKeyHEFNNWSXXWATRW-UHFFFAOYSA-N

CAS号15687-27-1

关联

1,001

项与布洛芬相关的临床试验

NCT06671002 / Not yet recruiting临床4期IIT

Comparing Analgesic Regimen Effectiveness and Safety for Surgery for Kids (CARES for Kids) Trial

This trial is being completed to compare two commonly used options to treat pain after discharge from surgery. Participants that undergo tonsil removal, gallbladder removal, and knee scope will be eligible to enroll. Eligible participants will be randomized to prescription of 1 of 2 groups of medications (Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) plus acetaminophen or low dose opioids with the NSAIDs plus acetaminophen. The key question the study seeks to answer is which option will have the best outcomes and with the fewest side effects?

开始日期2025-01-01

申办/合作机构

University of Michigan

[+1]

NCT06686862 / Not yet recruiting临床3期IIT

Non-Steroidal Anti-Inflammatory Drugs Versus Conventional Treatment in Acute Myocarditis (INFLAMA Trial)

Prospective, randomized, multicenter, open-label clinical trial to evaluate the safety and efficacy of a 3-week ibuprofen tapering regimen compared to conventional analgesic treatment (acetaminophen) in patients with acute myocarditis and left ventricular ejection fraction ≥50%. The objective is to assess the reduction in late gadolinium enhancement on cardiac magnetic resonance imaging at 6-month follow-up.

开始日期2024-12-01

申办/合作机构-

NCT06496854 / Not yet recruiting临床2期

Prescribing Lorazepam for IUD Insertion: Pilot Feasibility Study

The objective of this pilot study is to discuss the feasibility of prescribing lorazepam prior to IUD insertion and of measuring effect of lorazepam on anxiety and pain with Intrauterine Device (IUD) insertion. The target population for this study will be 25 adult participants scheduled for an IUD insertion at a UW Family Medicine residency clinic. Participants will be followed for 1 appointment visit.

开始日期2024-12-01

申办/合作机构

University of Wisconsin Madison

100 项与布洛芬相关的临床结果

登录后查看更多信息

100 项与布洛芬相关的转化医学

登录后查看更多信息

100 项与布洛芬相关的专利（医药）

登录后查看更多信息

16,592

项与布洛芬相关的文献（医药）

2025-09-01·Neural Regeneration Research

Modulation of the Nogo signaling pathway to overcome amyloid-β-mediated neurite inhibition in human pluripotent stem cell–derived neurites

Article

作者: Goncalves, Kirsty ; Przyborski, Stefan

JOURNAL/nrgr/04.03/01300535-202509000-00026/figure1/v/2024-11-05T132919Z/r/image-tiff Neuronal cell death and the loss of connectivity are two of the primary pathological mechanisms underlying Alzheimer’s disease. The accumulation of amyloid-β peptides, a key hallmark of Alzheimer’s disease, is believed to induce neuritic abnormalities, including reduced growth, extension, and abnormal growth cone morphology, all of which contribute to decreased connectivity. However, the precise cellular and molecular mechanisms governing this response remain unknown. In this study, we used an innovative approach to demonstrate the effect of amyloid-β on neurite dynamics in both two-dimensional and three-dimensional culture systems, in order to provide more physiologically relevant culture geometry. We utilized various methodologies, including the addition of exogenous amyloid-β peptides to the culture medium, growth substrate coating, and the utilization of human-induced pluripotent stem cell technology, to investigate the effect of endogenous amyloid-β secretion on neurite outgrowth, thus paving the way for potential future applications in personalized medicine. Additionally, we also explore the involvement of the Nogo signaling cascade in amyloid-β-induced neurite inhibition. We demonstrate that inhibition of downstream ROCK and RhoA components of the Nogo signaling pathway, achieved through modulation with Y-27632 (a ROCK inhibitor) and Ibuprofen (a Rho A inhibitor), respectively, can restore and even enhance neuronal connectivity in the presence of amyloid-β. In summary, this study not only presents a novel culture approach that offers insights into the biological process of neurite growth and inhibition, but also proposes a specific mechanism for reduced neural connectivity in the presence of amyloid-β peptides, along with potential intervention points to restore neurite growth. Thereby, we aim to establish a culture system that has the potential to serve as an assay for measuring preclinical, predictive outcomes of drugs and their ability to promote neurite outgrowth, both generally and in a patient-specific manner.

2025-01-01·Food Chemistry

Green synthesis and two-step chromatographic separation of thiocanthal and thiocanthol: Two novel biologically active sulfur derivatives of oleocanthal and oleacein from extra virgin olive oil

Article

作者: Gasparrini, Francesco ; Dainese, Enrico ; Di Risola, Daniel ; Fontana, Mario ; Federico, Rodolfo ; Mosca, Luciana ; Francioso, Antonio ; Mattioli, Roberto ; Dufrusine, Beatrice ; Pascarella, Gianmarco ; Morea, Veronica ; Ciogli, Alessia ; Villani, Claudio

Oleocanthal and oleacein are the two major secoiridoids exclusively present in extra virgin olive oil (EVOO). Both compounds exert important pharmacological activities, including anti-inflammatory, anti-tumoral, neuro- and cardiovascular protective effects. Due to their enormous potential as possible drugs the extraction of these two bioactive natural products from EVOO has been extensively investigated in the last years and is generally supported by the use of organic chemistry. It is quite difficult to produce large quantities of these two compounds, either by organic solvent extraction and purification or by chemical synthesis, and furthermore organic processes such as cleaning, defatting, and extraction of EVOO pose a threat to the environment and are potentially harmful to workers. In this work we set up a novel aqueous extraction and isolation method from EVOO by transforming oleocanthal and oleacein into two water-soluble sulfonated products. The two derived compounds, here named thiocanthal and thiocanthol, were isolated by a two-step organic free chromatographic strategy, chemically characterized, and evaluated for their inhibitory activity on cyclooxygenase (COX). The results demonstrate that thiocanthal and thiocanthol possess anti-inflammatory effect, which is comparable to their precursors and higher than the well-known non-steroidal anti-inflammatory drug ibuprofen. Computational docking studies were performed to obtain and analyse putative models of the interaction of thiocanthal and thiocanthol with COX-1 and COX-2 binding sites. Predicted binding energy values suggested that both compounds might preferentially bind COX-2, which may have a significant pharmacological impact. Therefore, thiocanthal and thiocanthol, obtained by this novel green process, are extremely interesting both as new bioactive compounds per se and as lead compounds for the development of novel non-steroidal anti-inflammatory drugs (NSAIDs).

2025-01-01·Journal of Ethnopharmacology

Bioactive phytocompounds profiling and the evaluation of analgesic, anti-inflammatory, and antihyperglycemic potential of Argyreia capitiformis (Poir.) Ooststr.: A combined n vitro, n vivo, and computational investigations

Article

作者: Islam, Md Naharul ; Biswas, Biswajit ; Islam, Md. Naharul ; Oisay, Debasree Sen ; Hasan, Md. Nazmul ; Hasan, Md Nazmul ; Biswas, Partha ; Medha, Maisha Maliha ; Devnath, Hiron Saraj ; Hossain, Arafat ; Sadhu, Samir Kumar ; Ahmed, Khondoker Shahin ; Hossain, Hemayet

ETHNOPHARMACOLOGICAL RELEVANCEArgyreia capitiformis (Poir.) Ooststr. (Convolvulaceae) is traditionally used by the Chakma community in the hilly region of Bangladesh to treat minor disorders such as pain.AIM OF THE STUDYThis study intended to determine the secondary metabolites to identify bioactive compounds and evaluate antioxidant potential, in vitro anti-inflammatory and in vivo analgesic, anti-inflammatory, and antihyperglycemic activities of A. capitiformis along with in silico investigations.MATERIALS AND METHODSChemical profiling was carried out using HPLC and GC-MS analysis. The analgesic effect was measured employing tail immersion and acetic acid-induced writhing methods. Following protein denaturation and formalin-induced paw edema, anti-inflammatory activity was studied. The antihyperglycemic potential was assessed using an oral glucose tolerance test (OGTT), while further mechanistic investigation was conducted using an alpha-glucosidase enzyme inhibitory assay. Simulations and molecular docking analyses were performed to ascertain the stability and binding affinities of the drug-protein complex.RESULTSA. capitiformis ethanolic extract confirmed the presence of phenolics, alkaloids, flavonoids, terpenoids, tannins, gums, steroids, and reducing sugars. HPLC analysis revealed the presence of eight polyphenolic compounds, the most abundant of which was myricetin (64.10 ± 0.14 mg per 100 g dry extract). Moreover, the GC-MS analysis revealed twenty-four molecules, the most important of which was 2,4-bis (dimethylbenzyl)-6-t-butylphenol (9.19%). The concentrations of total flavonoids, total terpenoids, total phenolics, and total tannins were ascertained to be 142.48 mg QE/g, 173.1 mg UAE/g, 19.35 mg GAE/g, and 13.05 mg GAE/g, respectively. Furthermore, the plant extract had a total antioxidant capacity of 388 mg AAE/g. In the writhing assay, the plant extract suppressed writhing by 59.73% and 76.99% at the doses of 250 and 500 mg/kg, respectively, compared to the standard diclofenac Na 87.17%, and in the tail immersion assay, the plant extract displayed a maximum average reaction time of 1.94 and 2.40 s at the doses of 250 and 500 mg/kg, respectively as compared to the control tramadol 2.84 s at 60 min. In an in vitro anti-inflammatory assay, the plant extract possessed an IC₅₀ of 95.51 μg/ml while diclofenac Na (standard drug) was found to be 69.50 μg/ml. Afterward, in vivo anti-inflammatory activity was observed in mice over a period, particularly after 3 h, the plant extract exerted maximum percent inflammation inhibitions of 36.36% and 45.45% at the doses of 250 and 500 mg/kg, respectively whereas ibuprofen the standard drug (100 mg/kg) exhibited 61.82%. The plant extract demonstrated antihyperglycemic activity, lowering blood sugar levels to 5.7 and 4.62 mM at doses of 250 and 500 mg/kg, respectively, as opposed to 8.58 mM in the control group. Meanwhile, the standard drug glibenclamide (5 mg/kg) dropped blood glucose levels to 2.38 mM in 60 min after glucose administration. Molecular docking (MD) and molecular dynamics simulation (MDS) studies support the stability of the protein complex responsible for exerting pharmacological activities.CONCLUSIONA. capitiformis extract exhibited strong medicinal values supporting its traditional uses.

675

项与布洛芬相关的新闻（医药）

2024-11-18

·drugs

Certain Painkillers Can Raise Bleeding Risks for People on Blood Thinners

MONDAY, Nov. 18, 2024 -- People on blood thinners have a doubled risk of dangerous internal bleeding if they also take a non-steroidal anti-inflammatory drug (NSAID) like ibuprofen or naproxen, a new study warns. People typically are prescribed blood thinners to treat or prevent strokes , heart attacks, or blood clots in the legs or lungs, researchers said. NSAIDs also are known to thin the blood, and the new study shows that they can increase risk of uncontrolled bleeding in the gut, brain, lungs and bladder if taken alongside a blood thinner. “We found that for patients taking blood thinners for blood clots in the legs or lungs, using NSAIDs doubled the risk of bleeding compared with not using NSAIDs,” said researcher Soren Riis Peterson , a medical student with Aarhus University Hospital in Denmark. “The increased bleeding risk associated with NSAID use was not limited to the digestive tract but also seemed to affect other organ systems.” For the study, researchers analyzed data on nearly 52,000 Danish patients prescribed a blood thinner to treat a blood clot between 2012 and 2022. In Denmark, the NSAIDs diclofenac and naproxen can only be obtained through a prescription. This allowed researchers to track the health of patients who had been prescribed both a blood thinner and an NSAID. Overall, the risk of a bleed was two times higher when people took a blood thinner and an NSAID, compared to just taking a blood thinner, researchers found. The specific risk was four times higher for naproxen, three times higher for diclofenac and nearly twice as high for ibuprofen. Specific bleed risks included: Using NSAIDs with a blood thinner also tripled a person’s risk of anemia, researchers found. The pattern of risk remained similar across a wide variety of blood thinners, including rivaroxaban , apixaban , dabigatran , edoxaban and warfarin , results show. The new study was published Nov. 17 in the European Heart Journal . “For people taking blood thinners for blood clots in their legs or lungs, our research highlights the importance of being cautious when considering NSAIDs for pain or inflammation,” Petersen concluded in a journal news release. “We recommend that patients consult their doctor before taking NSAIDs along with a blood thinner.” In an accompanying editorial, Dr. Robert Storey , a professor of clinical cardiology with the University of Sheffield in the U.K., noted that NSAIDs are widely used, making up about 8% of prescriptions worldwide and often available over-the-counter. “It seems clear that avoiding NSAIDs in combination with [blood thinners] is the safest strategy to avoid excess bleeding risk,” Storey wrote. “However, if this is not possible, what mitigation can be put in place? NSAID prescription should obviously be at the lowest dose and for the shortest time possible, but choice of agent and route may also be important.” Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

AHA会议

2024-11-18

·drugs

Bleeding Risk Increased With NSAID Use for VTE Patients Receiving Anticoagulants

MONDAY, Nov. 18, 2024 -- Patients with venous thromboembolism (VTE) initiating oral anticoagulants have an increased risk for bleeding when using nonsteroidal anti-inflammatory drugs (NSAIDs), according to a study published online Nov. 17 in the European Heart Journal . Søren Riis Petersen, from Aarhus University Hospital in Denmark, and colleagues conducted a nationwide cohort study of 51,794 VTE patients initiating oral anticoagulants between Jan. 1, 2012, and Dec. 31, 2022. Adjusted hazard ratios between NSAID use and hospital-diagnosed bleeding episodes were computed. The researchers found that the event rates for any bleeding per 100 person-years were 3.5 and 6.3 during periods without and with NSAID use, respectively (number needed to harm, 36 patients treated for one year). The adjusted hazard ratios for any bleeding associated with NSAID use versus nonuse were 2.09, 1.79, 3.30, and 4.10 overall, for ibuprofen, for diclofenac, and for naproxen, respectively. The adjusted hazard ratios associated with NSAID use versus nonuse were 2.24, 3.22, 1.36, 1.57, and 2.99 for gastrointestinal bleeding, intracranial bleeding, thoracic and respiratory tract bleeding, urinary tract bleeding, and anemia caused by bleeding, respectively. For anticoagulant and VTE subtypes, the results were consistent. "The common use of NSAIDs in patients with cardiovascular disease emphasizes the importance of being aware of the bleeding risks associated with their use," the authors write. Several authors disclosed ties to the pharmaceutical industry. Abstract/Full Text Editorial Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

AHA会议

2024-11-10

·信狐药迅

一线治疗非小细胞肺癌！上海倍而达三代EGFR抑制剂「瑞齐替尼」新适应症获批上市| 新获批（11.4-11.10）

每周药品注册获批数据，分门别类呈现，一目了然。(11.4-11.10）新药上市申请药品名称企业注册分类受理号甲磺酸瑞齐替尼胶囊上海倍而达药业有限公司1CXHS2400007盐酸凯普拉生片江苏柯菲平医药股份有限公司2.4CXHS2300078聚乙二醇重组人生长激素注射液长春金赛药业有限责任公司2.2CXSS2300057 新药临床申请药品名称企业注册分类受理号CPI-818片嘉兴和剂药业有限公司1CXHL2400893CPI-818片嘉兴和剂药业有限公司1CXHL2400892HYP-6589片四川汇宇海玥医药科技有限公司1CXHL2400863HYP-6589片四川汇宇海玥医药科技有限公司1CXHL2400862LPM682000012片山东绿叶制药有限公司1CXHL2400827LPM682000012片山东绿叶制药有限公司1CXHL2400826LPM682000012片山东绿叶制药有限公司1CXHL2400825BCM899颗粒上海云晟研新生物科技有限公司2.2CXHL2400858BCM899颗粒上海云晟研新生物科技有限公司2.2CXHL2400857注射用艾博韦泰前沿生物药业(南京)股份有限公司2.4CXHL2400865利多卡因丙胺卡因气雾剂江苏联环药业股份有限公司3CYHL2400176雷诺嗪缓释片北京阳光诺和药物研究股份有限公司3CYHL2400173雷诺嗪缓释片北京阳光诺和药物研究股份有限公司3CYHL2400172四价流感重组蛋白疫苗广东华南疫苗股份有限公司1.3CXSL24005289MW2821迈威(上海)生物科技股份有限公司1CXSL2400572ZT006片北京质肽生物医药科技有限公司1CXSL2400569ZT006片北京质肽生物医药科技有限公司1CXSL2400568ZT006片北京质肽生物医药科技有限公司1CXSL2400567ZT006片北京质肽生物医药科技有限公司1CXSL2400566ZT006片北京质肽生物医药科技有限公司1CXSL2400565ZT006片北京质肽生物医药科技有限公司1CXSL2400564CM512注射液康诺亚生物医药科技(成都)有限公司1CXSL2400560CM512注射液康诺亚生物医药科技(成都)有限公司1CXSL2400559艾米迈托赛注射液铂生卓越生物科技(北京)有限公司1CXSL2400557RJMty19注射液浙江瑞加美生物科技有限公司1CXSL2400553JCXH-211注射液嘉晨西海(杭州)生物技术有限公司1CXSL2400540靶向CD19非病毒PD1定点整合CAR-T细胞注射液上海邦耀生物科技有限公司1CXSL2400533 仿制药申请药品名称企业注册分类受理号维生素B6注射液江苏润恒制药有限公司3CYHS2402860复方聚乙二醇电解质散(II)南京海纳制药有限公司3CYHS2400148复方聚乙二醇电解质散(II)黑龙江博宇制药有限公司3CYHS2303588注射用拉氧头孢钠山东晶辉生物技术有限公司3CYHS2303220注射用拉氧头孢钠山东晶辉生物技术有限公司3CYHS2303219注射用拉氧头孢钠山东晶辉生物技术有限公司3CYHS2303221帕拉米韦注射液陕西博森生物制药股份集团有限公司3CYHS2302082注射用盐酸罗沙替丁醋酸酯郑州维先医药科技有限公司3CYHS2301977硝普钠注射液成都新恒创药业有限公司3CYHS2301634盐酸多巴酚丁胺注射液成都瑞尔医药科技有限公司3CYHS2301571依巴斯汀口服溶液湖南金圃医药科技有限公司3CYHS2301495法莫替丁注射液四川制药制剂有限公司3CYHS2301317盐酸丙卡特罗口服溶液南京艾德加生物制药科技有限公司3CYHS2301170盐酸丙卡特罗口服溶液南京艾德加生物制药科技有限公司3CYHS2301169膦甲酸钠注射液华仁药业股份有限公司3CYHS2301137己酮可可碱注射液武汉海特生物制药股份有限公司3CYHS2301000盐酸昂丹司琼片杭州和泽坤元药业有限公司3CYHS2300910盐酸昂丹司琼片杭州和泽坤元药业有限公司3CYHS2300909盐酸去氧肾上腺素注射液石家庄四药有限公司3CYHS2300901聚乙烯醇滴眼液四川海梦智森生物制药有限公司3CYHS2300897帕米膦酸二钠注射液仁合益康集团有限公司3CYHS2300892头孢氨苄干混悬剂上海金城素智药业有限公司3CYHS2300839盐酸去氧肾上腺素注射液南京恒道医药科技股份有限公司3CYHS2300808甲氨蝶呤片江苏百奥信康医药科技有限公司3CYHS2300574左亚叶酸钙注射液浙江普利药业有限公司3CYHS2300334左亚叶酸钙注射液浙江普利药业有限公司3CYHS2300333左亚叶酸钙注射液浙江普利药业有限公司3CYHS2300332左亚叶酸钙注射液浙江普利药业有限公司3CYHS2300331盐酸多巴酚丁胺注射液浙江沣华医药科技有限公司3CYHS2300301布洛芬混悬滴剂天大医药科技(珠海)有限公司3CYHS2300001国;CYHS2300001米诺地尔搽剂浙江远力健药业有限责任公司3CYHS2201287国;CYHS2201287注射用头孢唑肟钠山东晶辉生物技术有限公司4CYHS2403004注射用头孢唑肟钠山东晶辉生物技术有限公司4CYHS2403003注射用头孢唑肟钠山东晶辉生物技术有限公司4CYHS2403002盐酸曲唑酮缓释片山东京卫制药有限公司4CYHS2401449盐酸曲唑酮缓释片山东京卫制药有限公司4CYHS2401448地夸磷索钠滴眼液江苏远恒药业有限公司4CYHS2400248氧(液态)重庆川维林德气体有限责任公司4CYHS2400178麦考酚钠肠溶片山东新时代药业有限公司4CYHS2303659巴氯芬片重庆士立德医药科技有限公司4CYHS2302507玻璃酸钠滴眼液山东华鲁制药有限公司4CYHS2302277阿戈美拉汀片宝利化(南京)制药有限公司4CYHS2302145左卡尼汀口服溶液浙江长典药物技术开发有限公司4CYHS2302108玻璃酸钠滴眼液安徽环球药业股份有限公司4CYHS2301914玻璃酸钠滴眼液安徽环球药业股份有限公司4CYHS2301913注射用头孢唑肟钠海南全星制药有限公司4CYHS2301760硫辛酸注射液江苏睿实生物科技有限公司4CYHS2301742注射用头孢唑肟钠广州艾奇西新药研究有限公司4CYHS2301641左卡尼汀注射液舒美奇成都生物科技有限公司4CYHS2301604左卡尼汀注射液舒美奇成都生物科技有限公司4CYHS2301603马来酸氟伏沙明片上海理想制药有限公司4CYHS2301497莫匹罗星软膏河南羚锐制药股份有限公司4CYHS2301424二甲双胍恩格列净片天大药业(珠海)有限公司4CYHS2301425马来酸阿法替尼片江苏华阳制药有限公司4CYHS2301281伏立康唑干混悬剂健康元药业集团股份有限公司4CYHS2301217左氧氟沙星滴眼液石家庄凯赛医药科技有限公司4CYHS2301194瑞巴派特片福安药业集团宁波天衡制药有限公司4CYHS2301188熊去氧胆酸胶囊浙江寰领医药科技有限公司4CYHS2300582左氧氟沙星片吉林长白山药业集团股份有限公司4CYHS2300552地夸磷索钠滴眼液南京黄龙生物科技有限公司4CYHS2300464阿加曲班注射液海南葫芦娃药业集团股份有限公司4CYHS2300184克林霉素磷酸酯外用溶液江苏知原药业股份有限公司4CYHS2300147注射用替考拉宁海南倍特药业有限公司4CYHS2300059盐酸环喷托酯滴眼液山东绅联药业股份有限公司4CYHS2300007国;CYHS2300007盐酸美金刚片成都百裕制药股份有限公司4CYHS2201963国;CYHS2201963盐酸乐卡地平片兆科药业(广州)有限公司4CYHS2201840国;CYHS2201840注射用替考拉宁四川汇宇制药股份有限公司4CYHS2201554国;CYHS2201554注射用替考拉宁四川汇宇制药股份有限公司4CYHS2201552国;CYHS2201552注射用多种维生素(12)山东鲁盛制药有限公司4CYHS2201289国;CYHS2201289沙库巴曲缬沙坦钠片山东凤凰制药股份有限公司4CYHS2200423国;CYHS2200423屈螺酮炔雌醇片南通联亚药业股份有限公司4CYHS2200412国;CYHS2200412乌司奴单抗注射液杭州中美华东制药有限公司3.3CXSS2300065 进口申请药品名称企业注册分类受理号甲苯磺酸他拉唑帕利胶囊Pfizer Europe MA EEIG2.4JXHS2300032甲苯磺酸他拉唑帕利胶囊Pfizer Europe MA EEIG2.4JXHS2300031甲苯磺酸他拉唑帕利胶囊Pfizer Europe MA EEIG2.4JXHS2300030甲苯磺酸他拉唑帕利胶囊Pfizer Europe MA EEIG2.4JXHS2300029灌注用盐酸氨酮戊酸己酯Photocure ASA5.1JXHS2300108Acalabrutinib Maleate片AstraZeneca Pty Ltd.5.1JXHS2300077Acalabrutinib Maleate片AstraZeneca Pty Ltd.5.1JXHS2300076阿伐可泮硬胶囊Vifor Fresenius Medical Care Renal Pharma France5.1JXHS2200125国;JXHS2200125纳武利尤单抗注射液Bristol-Myers Squibb Pharma EEIG2.2JXSS2400015纳武利尤单抗注射液Bristol-Myers Squibb Pharma EEIG2.2JXSS2400014冻干膀胱灌注用卡介苗(日本株)Japan BCG Laboratory3.1JXSS2400032伊布替尼胶囊Natco Pharma Limited5.2JYHS2300009恩扎卢胺软胶囊Dr. Reddy's Laboratories Limited5.2JYHS2200042国;JYHS2200042AMG 193Amgen Inc.1JXHL2400211 中药相关申请药品名称企业注册分类受理号椒七麝凝胶贴膏湖南九典制药股份有限公司1.1CXZS2300028 注：橙色字体部分结论为不批准或收到通知件；

细胞疗法免疫疗法疫苗申请上市临床申请

100 项与布洛芬相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00126	布洛芬	M02AA13 R02AX02 M01AE01 G02CC01 C01EB16	DB01050

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
动脉导管未闭	欧盟	Recordati Rare Diseases, Inc.	2004-07-28
动脉导管未闭	列支敦士登	Recordati Rare Diseases, Inc.	2004-07-28
动脉导管未闭	冰岛	Recordati Rare Diseases, Inc.	2004-07-28
动脉导管未闭	挪威	Recordati Rare Diseases, Inc.	2004-07-28
慢性疼痛	澳大利亚	Viatris Pty Ltd.	2001-11-12
幼年特发性关节炎	澳大利亚	Viatris Pty Ltd.	2001-11-12
骨关节炎	澳大利亚	Viatris Pty Ltd.	2001-11-12
原发性痛经	澳大利亚	Viatris Pty Ltd.	2001-11-12
急性上呼吸道感染	日本	Kaken Pharmaceutical Co., Ltd.	1971-06-25
炎症	日本	Kaken Pharmaceutical Co., Ltd.	1971-06-25
类风湿关节炎	英国	Johnson & Johnson	1969-01-01
关节炎	中国	丹东医创药业有限责任公司	1966-01-01
发热	中国	丹东医创药业有限责任公司	1966-01-01
疼痛	中国	丹东医创药业有限责任公司	1966-01-01

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
发热	临床3期	泰国	Cumberland Pharmaceuticals, Inc.	2002-06-01
骨关节炎	临床3期	美国	McNeil Consumer Healthcare Division of McNEIL-PPC, Inc.	1974-09-19
疼痛	临床3期	美国	McNeil Consumer Healthcare Division of McNEIL-PPC, Inc.	1974-09-19
疼痛	临床3期	美国	McNeil Consumer Healthcare Division of McNEIL-PPC, Inc.	1974-09-19
发热	临床2期	泰国	Cumberland Pharmaceuticals, Inc.	2002-06-01
疼痛	临床2期	美国	McNeil Consumer Healthcare Division of McNEIL-PPC, Inc.	1974-09-19

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


PRNewswire 人工标引	N/A	疼痛	-	Caldolor (ibuprofen) injection	構壓鏇網艱膚鹽鑰顧構(醖積構糧繭鏇窪築網簾) = 蓋淵觸壓衊蓋範觸遞構觸廠顧膚網選簾蓋範憲 (壓窪餘淵窪網願廠觸淵 ) 更多	积极	2024-11-05
				ketorolac	-
NCT04611529 (CTgov)	临床4期	急性腰痛	198	Topical diclofenac+Ibuprofen 400 mg (Oral Ibuprofen + Topical Diclofenac)	餘夢鹽簾積廠淵憲淵遞(糧觸鹹膚艱顧艱鹽鑰餘) = 簾齋憲襯網鬱襯憲積築憲淵鏇蓋憲廠艱積窪觸 (膚膚鏇鬱顧蓋網憲壓鹽, 製鬱壓鏇網窪膚鬱獵繭 ~ 構淵淵築襯網獵鬱製夢) 更多	-	2024-10-09
				Ibuprofen 400 mg (Oral Ibuprofen + Topical Placebo)	餘夢鹽簾積廠淵憲淵遞(糧觸鹹膚艱顧艱鹽鑰餘) = 製觸鹽壓淵襯鹽鹽衊網憲淵鏇蓋憲廠艱積窪觸 (膚膚鏇鬱顧蓋網憲壓鹽, 壓製窪簾夢鏇選窪繭顧 ~ 簾顧築夢夢獵簾襯衊顧) 更多
NCT03859024 (CTgov)	临床4期	尿道狭窄 \| 术后疼痛	48	Acetaminophen+Ibuprofen 800 mg+Oxycodone (Standard Protocol)	淵顧遞獵構範鏇餘願範(積憲衊夢壓衊壓鏇獵觸) = 觸憲構襯鏇積夢糧衊鏇鬱築蓋鹽壓醖遞壓蓋獵 (遞醖糧膚遞鏇網襯範餘, 夢獵膚夢淵淵觸鹹築製 ~ 廠鏇獵簾鬱廠廠構襯淵) 更多	-	2024-09-19
				Acetaminophen+Ibuprofen 800 mg+celebrex+Dexamethasone+Oxycodone+Bupivacaine+Gabapentin (Enhanced Recovery Protocol)	淵顧遞獵構範鏇餘願範(積憲衊夢壓衊壓鏇獵觸) = 鏇選製願簾選簾壓獵蓋鬱築蓋鹽壓醖遞壓蓋獵 (遞醖糧膚遞鏇網襯範餘, 範製艱鹹製糧鑰鬱齋鹹 ~ 膚壓窪襯選遞壓憲觸製) 更多
NCT05737069 (CTgov)	临床1期	疼痛	84	Ibuprofen Arginine (Fasted Cohort: Ibuprofen Arginine Granules 400 mg (Test))	膚築鬱遞壓糧繭遞憲構(憲網餘願鑰製蓋願繭簾) = 餘鏇窪鹹夢壓獵鹽構醖壓簾範積艱憲觸醖壓顧 (選觸鏇鬱齋簾窪廠構鏇, 蓋壓繭觸壓淵壓觸夢遞 ~ 願鹽壓憲觸築獵獵襯構) 更多	-	2024-09-19
				Ibuprofen Arginine (Fasted Cohort: Ibuprofen Arginine Granules 400 mg (Spedifen) (Reference))	膚築鬱遞壓糧繭遞憲構(憲網餘願鑰製蓋願繭簾) = 網膚餘壓積齋窪夢構淵壓簾範積艱憲觸醖壓顧 (選觸鏇鬱齋簾窪廠構鏇, 築醖鬱鬱淵觸壓夢遞衊 ~ 廠鬱衊衊遞艱鬱遞鬱窪) 更多
NCT04879823 (CTgov)	临床3期	镇痛	222	Acetaminophen+Ibuprofen+Dexamethasone (Dexamethasone)	構範鏇憲築積艱餘築繭(淵鏇製獵選簾繭壓齋襯) = 襯觸醖艱築夢願築蓋選夢窪願夢築膚顧壓鏇獵 (選顧獵衊鹽選鬱遞齋顧, 壓夢構觸鏇積壓窪廠壓 ~ 網觸糧衊壓願鬱繭積襯) 更多	-	2024-09-05
				Placebo+Acetaminophen+Ibuprofen (Placebo)	構範鏇憲築積艱餘築繭(淵鏇製獵選簾繭壓齋襯) = 願齋餘鬱淵鬱繭繭醖願夢窪願夢築膚顧壓鏇獵 (選顧獵衊鹽選鬱遞齋顧, 壓鹹淵艱範壓鬱積繭壓 ~ 窪壓齋鹹網窪淵窪鏇齋) 更多
NCT03749616 (Adult NSAID, CTgov)	临床4期	疼痛 \| 桡骨骨折	32	Acetaminophen (Acetaminophen)	鹹憲範齋積選製衊壓淵(憲醖艱製獵顧壓積範壓) = 糧鹽選膚觸衊淵衊觸蓋襯觸構夢獵齋膚窪鏇鏇 (廠餘範構鏇築範鏇簾構, 餘願壓鹽淵膚醖簾衊糧 ~ 選艱鏇糧齋獵鹹觸繭齋) 更多	-	2024-09-05
				Ibuprofen (NSAID)	鹹憲範齋積選製衊壓淵(憲醖艱製獵顧壓積範壓) = 餘鏇鹹齋築獵網餘壓鹹襯觸構夢獵齋膚窪鏇鏇 (廠餘範構鏇築範鏇簾構, 壓製繭鹽鏇憲範糧鑰糧 ~ 醖醖襯積鏇艱齋膚膚壓) 更多
NCT03929640 (CTgov)	临床3期	术后疼痛	49	Placebo+Ibuprofen (Ibuprofen and Placebo)	糧淵選鹽衊糧糧網鹹顧(製願壓顧艱顧淵窪選積) = 鏇觸憲遞範齋範壓蓋積餘襯鏇廠繭遞蓋觸鹹壓 (積憲選製艱壓鹹顧鏇糧, 憲鏇網廠網鬱夢顧艱鹹 ~ 範簾鏇簾夢繭構餘襯築) 更多	-	2024-09-04
				Acetaminophen+Ibuprofen (Ibuprofen and Acetaminophen)	糧淵選鹽衊糧糧網鹹顧(製願壓顧艱顧淵窪選積) = 齋糧鏇網淵觸簾顧襯餘餘襯鏇廠繭遞蓋觸鹹壓 (積憲選製艱壓鹹顧鏇糧, 淵衊選廠廠憲鹹繭壓淵 ~ 壓製獵醖網糧構願簾範) 更多
NCT04791761 (CTgov)	临床1/2期	术后疼痛	73	Opioid disposal education+Acetaminophen+Ibuprofen+Oxycodone (Opioid Pain Control)	膚願壓繭淵夢窪糧願窪(膚觸廠艱積衊壓鏇餘鑰) = 窪製網蓋鬱願衊選簾鑰壓糧鬱壓鹹鏇範蓋膚範 (鹹願淵淵遞選願蓋鬱簾, 鏇餘顧鏇簾淵構鬱齋齋 ~ 網積網鹽築鏇顧襯鏇選) 更多	-	2024-08-16
				Acetaminophen+Ibuprofen (Non-opioid Pain Control)	膚願壓繭淵夢窪糧願窪(膚觸廠艱積衊壓鏇餘鑰) = 糧獵窪構蓋築糧築窪構壓糧鬱壓鹹鏇範蓋膚範 (鹹願淵淵遞選願蓋鬱簾, 憲壓選窪遞構觸積選艱 ~ 淵壓獵齋簾壓齋獵遞艱) 更多
NCT03399318 (Pubmed)	临床3期	疟疾	256	Aggressive antipyretic therapy (acetaminophen + ibuprofen)	艱築衊襯餘壓襯齋遞網(選襯範齋鏇憲夢鏇窪壓) = 鏇糧蓋構壓顧壓鬱鑰顧構醖顧鑰獵觸餘壓蓋網 (憲蓋鏇觸製繭醖簾壓鏇, -0.62) 更多	积极	2024-06-10
				Usual care (acetaminophen alone)	艱築衊襯餘壓襯齋遞網(選襯範齋鏇憲夢鏇窪壓) = 鬱壓夢壓構壓襯夢獵衊構醖顧鑰獵觸餘壓蓋網 (憲蓋鏇觸製繭醖簾壓鏇, -0.82 ~ -0.42) 更多
NCT03785756 (CTgov)	临床3期	疼痛	280	Placebo of IR tablet+Ibuprofen 300 mg Oral Tablet (Prolonged Release Group)	窪製鬱繭鏇範獵艱築艱(膚廠鹽艱獵膚齋顧齋憲) = 壓範廠衊鑰構鏇膚鹽蓋襯鬱糧築觸壓積網簾糧 (鏇醖壓顧網夢網製糧選, 膚顧餘選網衊醖繭艱醖 ~ 選鬱製鹹鹽觸廠繭顧餘) 更多	-	2024-06-03
				Placebo of IR tablet+Ibuprofen 200 mg Oral Tablet (Immediate Release Group)	窪製鬱繭鏇範獵艱築艱(膚廠鹽艱獵膚齋顧齋憲) = 願壓繭衊繭蓋製願顧顧襯鬱糧築觸壓積網簾糧 (鏇醖壓顧網夢網製糧選, 醖鹹膚廠顧鑰糧製觸簾 ~ 膚衊願選築憲廠範鏇製) 更多